Industry groups urge members to submit DIR comments to CMS by Jan. 25NACDS and NCPA are urging members to send comments about DIR fees to CMS by Jan. 25. OTC monograph reform passes HouseThe House of Representatives on Tuesday passed H.R. 269 — a package of bills that legislation aimed at modernizing the OTC monograph process — gaining praise from industry organizations. Acorda Therapeutics' Inbrija gets approval Acorda Therapeutics' Inbrija helps patients who may experience OFF episodes as Parkinson’s progresses. Cardinal Health Foundation provides grant for Ohio opioid initiative The Cardinal Health Foundation is providing a $530,000 grant to fight opioid misuse and abuse. FDA approves Lupin's generic Latuda Lupin has received the FDA's approval for generic Latuda tablets, which had a market value of roughly $3.2 billion. Pliaglis’ ‘Not for Home Use’ label restriction gets green lighted Crescita's Pliaglis received approval from the Food and Drug Administration for removal of the "Not for Home Use" label restriction. Hy-Vee implements controlled substance prescription policy Hy-Vee's pharmacies are aiming to combat the opioid epidemic with a new controlled substance prescription policy. Braeburn's Brixadi gets tentative approval Braeburn's Brixadi offers treatment for patients with moderate-to-severe opioid use disorder. Alembic gets approval for 2 generics The FDA has approved Alembic's generic Mirapex and Patanol, which had a market value of roughly $38.6 million, and $61 million, respectively. Lupin, AbbVie partner to develop cancer drugs Lupin and AbbVie have formed a partnership to develop Lupin's MALT1 inhibitors. First Previous 25 26 27 28 29 Next Last
